威尔药业
(603351)
| 流通市值：38.33亿 | | | 总市值：38.33亿 |
| 流通股本：1.35亿 | | | 总股本：1.35亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 349,725,188.55 | 1,296,753,389.06 | 1,000,364,429.23 | 688,157,870.31 |
| 营业收入 | 349,725,188.55 | 1,296,753,389.06 | 1,000,364,429.23 | 688,157,870.31 |
| 二、营业总成本 | 307,861,914.39 | 1,137,417,233.03 | 886,687,537.69 | 606,291,744.8 |
| 营业成本 | 258,644,574.16 | 929,479,269.55 | 741,019,493.32 | 509,259,176.74 |
| 税金及附加 | 2,194,359.96 | 8,701,785.7 | 6,702,957.05 | 4,396,367.44 |
| 销售费用 | 3,064,721.69 | 14,471,230.01 | 10,424,902.41 | 6,788,097.2 |
| 管理费用 | 22,880,583.92 | 101,371,471.57 | 71,277,490.08 | 47,400,775.59 |
| 研发费用 | 18,198,856.61 | 71,561,298.63 | 47,691,176.39 | 31,831,986.94 |
| 财务费用 | 2,878,818.05 | 11,832,177.57 | 9,571,518.44 | 6,615,340.89 |
| 其中:利息费用 | 2,921,468.84 | 13,837,458.66 | 10,548,555.71 | 7,615,042.57 |
| 其中:利息收入 | 144,450.19 | 925,452.55 | 746,897.77 | 428,681.34 |
| 加:公允价值变动收益 | - | 12,072,961.13 | 12,072,961.13 | 12,072,961.13 |
| 加:投资收益 | - | -68,939.98 | -68,940 | -68,940 |
| 资产处置收益 | 6,484.57 | - | - | - |
| 资产减值损失(新) | - | -9,014,547.81 | -3,847,764.11 | -3,847,764.11 |
| 信用减值损失(新) | -219,574.21 | -357,076.34 | -83,519.23 | -622,881.1 |
| 其他收益 | 1,369,147.84 | 10,381,884.36 | 7,148,520.41 | 5,305,081.05 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 43,019,332.36 | 172,350,437.39 | 128,898,149.74 | 94,704,582.48 |
| 减:营业外支出 | 69,616.87 | 219,173.52 | 167,145.27 | 72,842.95 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 42,949,715.49 | 172,131,263.87 | 128,731,004.47 | 94,631,739.53 |
| 减:所得税费用 | 7,183,536.95 | 26,925,425.17 | 17,699,818.17 | 16,918,489.14 |
| 六、净利润 | 35,766,178.54 | 145,205,838.7 | 111,031,186.3 | 77,713,250.39 |
| 持续经营净利润 | 35,766,178.54 | 145,205,838.7 | 111,031,186.3 | 77,713,250.39 |
| 归属于母公司股东的净利润 | 36,587,563.15 | 146,421,823.99 | 112,897,296.64 | 78,895,240.65 |
| 少数股东损益 | -821,384.61 | -1,215,985.29 | -1,866,110.34 | -1,181,990.26 |
| (一)基本每股收益 | 0.27 | 1.08 | 0.83 | 0.58 |
| (二)稀释每股收益 | 0.27 | 1.08 | 0.83 | 0.58 |
| 九、综合收益总额 | 35,766,178.54 | 145,205,838.7 | 111,031,186.3 | 77,713,250.39 |
| 归属于母公司股东的综合收益总额 | 36,587,563.15 | 146,421,823.99 | 112,897,296.64 | 78,895,240.65 |
| 归属于少数股东的综合收益总额 | -821,384.61 | -1,215,985.29 | -1,866,110.34 | -1,181,990.26 |
| 公告日期 | 2025-04-22 | 2025-04-22 | 2024-10-24 | 2024-08-20 |
| 审计意见(境内) | | 标准无保留意见 | | |